A Chimeric Dengue Virus Vaccine Candidate Delivered by High Density Microarray Patches Protects Against Infection in Mice

Overview

Journal NPJ Vaccines

Date 2021 May 8

PMID 33963191

Citations 19

Authors

Jovin J Y Choo

Laura J Vet

Christopher L D McMillan

Jessica J Harrison

Connor A P Scott

Alexandra C I Depelsenaire

Germain J P Fernando

Daniel Watterson

Roy A Hall

Paul R Young

Jody Hobson-Peters

David A Muller

Affiliations

Soon will be listed here.

Abstract

Dengue viruses (DENV) cause an estimated 390 million infections globally. With no dengue-specific therapeutic treatment currently available, vaccination is the most promising strategy for its control. A wide range of DENV vaccines are in development, with one having already been licensed, albeit with limited distribution. We investigated the immunogenicity and protective efficacy of a chimeric virus vaccine candidate based on the insect-specific flavivirus, Binjari virus (BinJV), displaying the structural prM/E proteins of DENV (BinJ/DENV2-prME). In this study, we immunized AG129 mice with BinJ/DENV2-prME via a needle-free, high-density microarray patch (HD-MAP) delivery system. Immunization with a single, 1 µg dose of BinJ/DENV2-prME delivered via the HD-MAPs resulted in enhanced kinetics of neutralizing antibody induction when compared to needle delivery and complete protection against mortality upon virus challenge in the AG129 DENV mouse model.

Citing Articles

Serum-Free Suspension Culture of the C6/36 Cell Line for Chimeric Orthoflavivirus Vaccine Production.

Dawurung J, Harrison J, Modhiran N, Hall R, Hobson-Peters J, de Malmanche H Viruses. 2025; 17(2).

PMID: 40007005 PMC: 11860912. DOI: 10.3390/v17020250.

Beyond the Needle: Innovative Microneedle-Based Transdermal Vaccination.

Nguyen H Medicines (Basel). 2025; 12(1).

PMID: 39982324 PMC: 11843882. DOI: 10.3390/medicines12010004.

Eilat virus isolated from Culex univittatus mosquitoes from the Namibian Zambezi Region influences in vitro superinfection with alpha- and flaviviruses in a virus-species-dependent manner.

Guggemos H, Kopp A, Voigt K, Fendt M, Graff S, Mfune J PLoS One. 2024; 19(12):e0312182.

PMID: 39705228 PMC: 11661592. DOI: 10.1371/journal.pone.0312182.

A chimeric vaccine derived from Australian genotype IV Japanese encephalitis virus protects mice from lethal challenge.

Harrison J, Nguyen W, Morgan M, Tang B, Habarugira G, de Malmanche H NPJ Vaccines. 2024; 9(1):134.

PMID: 39085247 PMC: 11291493. DOI: 10.1038/s41541-024-00903-2.

Insights into the Pathogenesis and Development of Recombinant Japanese Encephalitis Virus Genotype 3 as a Vaccine.

Park J, Lee H, Jun S, Kamitani W, Kim O, Shin H Vaccines (Basel). 2024; 12(6).

PMID: 38932326 PMC: 11209496. DOI: 10.3390/vaccines12060597.

References

Andreata-Santos R, Alves R, Pereira S, Pereira L, de Freitas C, Pereira S . Transcutaneous Administration of Dengue Vaccines. Viruses. 2020; 12(5). PMC: 7290698. DOI: 10.3390/v12050514. View

Moyle P . Biotechnology approaches to produce potent, self-adjuvanting antigen-adjuvant fusion protein subunit vaccines. Biotechnol Adv. 2017; 35(3):375-389. DOI: 10.1016/j.biotechadv.2017.03.005. View

Muller D, Fernando G, Owens N, Agyei-Yeboah C, Wei J, Depelsenaire A . High-density microprojection array delivery to rat skin of low doses of trivalent inactivated poliovirus vaccine elicits potent neutralising antibody responses. Sci Rep. 2017; 7(1):12644. PMC: 5626768. DOI: 10.1038/s41598-017-13011-0. View

Pierson T, Diamond M . Degrees of maturity: the complex structure and biology of flaviviruses. Curr Opin Virol. 2012; 2(2):168-75. PMC: 3715965. DOI: 10.1016/j.coviro.2012.02.011. View

Muller D, Depelsenaire A, Shannon A, Watterson D, Corrie S, Owens N . Efficient Delivery of Dengue Virus Subunit Vaccines to the Skin by Microprojection Arrays. Vaccines (Basel). 2019; 7(4). PMC: 6963636. DOI: 10.3390/vaccines7040189. View

Dejnirattisai W, Wongwiwat W, Supasa S, Zhang X, Dai X, Rouvinski A . A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus. Nat Immunol. 2014; 16(2):170-177. PMC: 4445969. DOI: 10.1038/ni.3058. View

Collins M, Metz S . Progress and Works in Progress: Update on Flavivirus Vaccine Development. Clin Ther. 2017; 39(8):1519-1536. DOI: 10.1016/j.clinthera.2017.07.001. View

Metz S, Thomas A, White L, Stoops M, Corten M, Hannemann H . Dengue virus-like particles mimic the antigenic properties of the infectious dengue virus envelope. Virol J. 2018; 15(1):60. PMC: 5879749. DOI: 10.1186/s12985-018-0970-2. View

Halstead S, ORourke E . Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody. J Exp Med. 1977; 146(1):201-17. PMC: 2180729. DOI: 10.1084/jem.146.1.201. View

10.

Martina B, Koraka P, Osterhaus A . Dengue virus pathogenesis: an integrated view. Clin Microbiol Rev. 2009; 22(4):564-81. PMC: 2772360. DOI: 10.1128/CMR.00035-09. View

11.

Warrilow D, Watterson D, Hall R, Davis S, Weir R, Kurucz N . A new species of mesonivirus from the Northern Territory, Australia. PLoS One. 2014; 9(3):e91103. PMC: 3966781. DOI: 10.1371/journal.pone.0091103. View

12.

Vet L, Setoh Y, Amarilla A, Habarugira G, Suen W, Newton N . Protective Efficacy of a Chimeric Insect-Specific Flavivirus Vaccine against West Nile Virus. Vaccines (Basel). 2020; 8(2). PMC: 7349994. DOI: 10.3390/vaccines8020258. View

13.

Tassaneetrithep B, Burgess T, Granelli-Piperno A, Trumpfheller C, Finke J, Sun W . DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells. J Exp Med. 2003; 197(7):823-9. PMC: 2193896. DOI: 10.1084/jem.20021840. View

14.

Forster A, Witham K, Depelsenaire A, Veitch M, Wells J, Wheatley A . Safety, tolerability, and immunogenicity of influenza vaccination with a high-density microarray patch: Results from a randomized, controlled phase I clinical trial. PLoS Med. 2020; 17(3):e1003024. PMC: 7077342. DOI: 10.1371/journal.pmed.1003024. View

15.

Fernando G, Chen X, Prow T, Crichton M, Fairmaid E, Roberts M . Potent immunity to low doses of influenza vaccine by probabilistic guided micro-targeted skin delivery in a mouse model. PLoS One. 2010; 5(4):e10266. PMC: 2858085. DOI: 10.1371/journal.pone.0010266. View

16.

Whitehead S, Falgout B, Hanley K, Blaney Jr J, Markoff L, Murphy B . A live, attenuated dengue virus type 1 vaccine candidate with a 30-nucleotide deletion in the 3' untranslated region is highly attenuated and immunogenic in monkeys. J Virol. 2002; 77(2):1653-7. PMC: 140839. DOI: 10.1128/jvi.77.2.1653-1657.2003. View

17.

Yan K, Vet L, Tang B, Hobson-Peters J, Rawle D, Le T . A Yellow Fever Virus 17D Infection and Disease Mouse Model Used to Evaluate a Chimeric Binjari-Yellow Fever Virus Vaccine. Vaccines (Basel). 2020; 8(3). PMC: 7564786. DOI: 10.3390/vaccines8030368. View

18.

Capeding M, Tran N, Hadinegoro S, Ismail H, Chotpitayasunondh T, Chua M . Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet. 2014; 384(9951):1358-65. DOI: 10.1016/S0140-6736(14)61060-6. View

19.

Zehrung D, Jarrahian C, Wales A . Intradermal delivery for vaccine dose sparing: overview of current issues. Vaccine. 2012; 31(34):3392-5. DOI: 10.1016/j.vaccine.2012.11.021. View

20.

Yacoub S, Lam P, Vu L, Le T, Ha N, Toan T . Association of Microvascular Function and Endothelial Biomarkers With Clinical Outcome in Dengue: An Observational Study. J Infect Dis. 2016; 214(5):697-706. PMC: 4978369. DOI: 10.1093/infdis/jiw220. View